Hyperfibrinogenemia is a useful predictor for lymphatic metastasis in human gastric cancer

Japanese Journal of Clinical Oncology

Volumn 35, Issue 10, 2005, Pages 595-600

  Yamashita, Hiroharu ^a   Kitayama, Joji ^a   Nagawa, Hirokazu ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

Fibrinogen; Gastric cancer; Hyperfibrinogenemia; Lymphatic metastasis; Signet ring cell carcinoma

Indexed keywords

C REACTIVE PROTEIN; CARCINOEMBRYONIC ANTIGEN; FIBRINOGEN;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADULT; ADVANCED CANCER; ARTICLE; CANCER CLASSIFICATION; CANCER SURGERY; CORRELATION ANALYSIS; FEMALE; FIBRINOGEN BLOOD LEVEL; HUMAN; LIVER METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PREDICTION; RETROSPECTIVE STUDY; STOMACH ADENOCARCINOMA; STOMACH CANCER;

ADENOCARCINOMA; C-REACTIVE PROTEIN; CARCINOEMBRYONIC ANTIGEN; CARCINOMA, SIGNET RING CELL; FEMALE; FIBRINOGEN; HUMANS; LIVER NEOPLASMS; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE OF TESTS; STOMACH NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 27944437493     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyi150     Document Type: Article

References (37)

1. Trousseau A. Phlegmasia alba. dolens. In: Clinique Medicale de L'Hotel Dieu de Paris, 2nd edn. Paris: Balliere 1865;654-6.
2. Sun NC, McAfee WM, Hum GJ, Weiner JM. Hemostatic abnormalities in malignancy, a prospective study of one hundred eight patients. Part I. Coagulation studies. Am J Clin Pathol 1979;71:10-6.
3. Luzzatto G, Schafer AI. The prethrombotic state in cancer. Semin Oncol 1990;17:147-59.
4. Lopez Y, Paloma MJ, Rifon J, Cuesta B, Paramo JA. Measurement of prethrombotic markers in the assessment of acquired hypercoagulable states. Thromb Res 1999;93:71-8.
5. Ikeda M, Furukawa H, Imamura H, Shimizu J, Ishida H, Masutani S, et al. Poor prognosis associated with thrombocytosis in patients with gastric cancer. Ann Surg Oncol 2002;9:287-91.
6. Shimada H, Oohira G, Okazumi S, Matsubara H, Nabeya Y, Hayashi H, et al. Thrombocytosis associated with poor prognosis in patients with esophageal carcinoma. J Am Coll Surg 2004;198:737-41.
7. Costantini V, Zacharski LR, Moritz TE, Edwards RL. The platelet count in carcinoma of the lung and colon. Thromb Haemost 1990;64:501-5.
8. Symbas NP, Townsend MF, El-Galley R, Keane TE, Graham SD, Petros JA. Poor prognosis associated with thrombocytosis in patients with renal cell carcinoma. BJU Int 2000;86:203-7.
9. Hernandez E, Donohue KA, Anderson LL, Heller PB, Stehman FB. The significance of thrombocytosis in patients with locally advanced cervical carcinoma: A Gynecologic Oncology Group study. Gynecol Oncol 2000;78:137-42.
10. Unsal E, Atalay F, Atikcan S, Yilmaz A. Prognostic significance of hemostatic parameters in patients with lung cancer. Respir Med 2004;98:93-8.
11. Buccheri G, Torchio P, Ferrigno D. Plasma levels of D-dimer in lung carcinoma: Clinical and prognostic significance. Cancer 2003;97:3044-52.
12. Oya M, Akiyama Y, Okuyama T, Ishikawa H. High preoperative plasma D-dimer level is associated with advanced tumor stage and short survival after curative resection in patients with colorectal cancer. Jpn J Clin Oncol 2001;31:388-94.
13. Blackwell K, Hurwitz H, Lieberman G, Novotny W, Snyder S, Dewhirst M, et al. Circulating D-dimer levels are better predictors of overall survival and disease progression than carcinoembryonic antigen levels in patients with metastatic colorectal carcinoma. Cancer 2004;101:77-82.
14. Dvorak HF. Thrombosis and cancer. Hum Pathol 1987;18:275-84.
15. Di Micco P, Romano M, Niglio A, Nozzolillo P, Federico A, Petronella P, et al. Alteration of haemostasis in non-metastatic gastric cancer. Dig Liver Dis 2001;33:546-50.
16. Lee JR, Ryu KW, Kim S, Bae JM. Preoperative plasma fibrinogen levels in gastric cancer patients correlate with extent of tumor. Hepatogastroenterology 2004;51:1860-3.
17. Palumbo JS, Kombrinck KW, Drew AF, Grimes TS, Kiser JH, Degen JL, et al. Fibrinogen is an important determinant of the metastatic potential of circulating tumor cells. Blood 2000;96:3302-9.
18. Palumbo JS, Potter JM, Kaplan LS, Talmage K, Jackson DG, Degen JL. Spontaneous hematogenous and lymphatic metastasis, but not primary tumor growth or angiogenesis, is diminished in fibrinogen-deficient mice. Cancer Res 2002;62:6966-72.
19. Japanese Gastric Cancer A. Japanese Classification of Gastric Carcinoma. 2nd English Edition. Gastric Cancer 1998;1:10-24.
20. TNM classification of malignant tumors. In: Sobin LH, Wittekind CH, editors. International Union Against Cancer, 5th edn. New York: John Willey & Sons 1997.
21. Wu CW, Wang SR, Chao MF, Wu TC, Lui WY, P'Eng FK, et al. Serum interleukin-6 levels reflect disease status of gastric cancer. Am J Gastroenterol 1996;91:1417-22.
22. Kabir S, Daar GA. Serum levels of interleukin-1, interleukin-6 and tumour necrosis factor-alpha in patients with gastric carcinoma. Cancer Lett 1995;95:207-12.
23. Radochova D, Chrobak L, Bartos V, Brzek V, Strnad L. The human thoracic duct lymph. Quantitative and qualitative analysis of the cellular composition of the lymph. Sb Ved Pr Lek Fak Karlovy Univerzity Hradci Kralove 1976;19:537-51.
24. Podgrabinska S, Braun P, Velasco P, Kloos B, Pepper MS, Skobe M. Molecular characterization of lymphatic endothelial cells. Proc Natl Acad Sci USA 2002;99:16069-74.
25. Miller GJ, Howarth DJ, Attfield JC, Cooke CJ, Nanjee MN, Olszewski WL, et al. Haemostatic factors in human peripheral afferent lymph. Thromb Haemost 2000;83:427-32.
26. DeAnglis AP, Einhaus CM, Sombun AD, Ee LC, Retzinger GS. Fibrinogen in rat gastrointestinal lymph before, during and after intraduodenal administration of emulsified triglyceride: Fibrinogen bound to chylomicrons in gastrointestinal lymph is functional. Thromb Res 2002;105:419-32.
27. Day ED, Planinsek JA, Pressman D. Localization of radioiodinated rat fibrinogen in transplanted rat tumors. J Natl Cancer Inst 1959;23:799-812.
28. Brown LF, Van de Water L, Harvey VS, Dvorak HF. Fibrinogen influx and accumulation of cross-linked fibrin in healing wounds and in tumor stroma. Am J Pathol 1988;130:455-65.
29. Dvorak HF, Brown LF, Detmar M, Dvorak AM. Vascular permeability factor/ vascular endothelial growth factor, microvascular hyperpermeability, and angiogenosis. Am J Pathol 1995;146: 1029-39.
30. Dvorak HF. Vascular permeability factor/vascular endothelial growth factor: A critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 2002;20:4368-80.
31. Rickles FR, Hancock WW, Edwards RL, Zacharski LR. Antimetastatic agents. I. Role of cellular procoagulants in the pathogenesis of fibrin deposition in cancer and the use of anticoagulants and/or antiplatelet drugs in cancer treatment. Semin Thromb Hemost 1988;14:88-94.
32. Hogg N. Human monocytes have prothrombin cleaving activity. Clin Exp Immunol 1983;53:725-30.
33. Nagy JA, Brown LF, Senger DR, Lanir N, Van de Water L, Dvorak AM, et al. Pathogenesis of tumor stroma generation: A critical role for leaky blood vessels and fibrin deposition. Biochim Biophys Acta 1989;948:305-26.
34. Bardos H, Juhasz A, Repassy G, Adany R. Fibrin deposition in squamous cell carcinomas of the larynx and hypopharynx. Thromb Haemost 1998;80:767-72.
35. Kerlin B, Cooley BC, Isermann BH, Hernandez I, Sood R, Zogg M, et al. Cause-effect relation between hyperfibrinogenemia and vascular disease. Blood 2004;103:1728-34.
36. Costantini V, Zacharski LR. The role of fibrin in tumor metastasis. Cancer Metastasis Rev 1992;11:283-90.
37. Takahashi Y, Cleary KR, Mai M, Kitadai Y, Bucana CD, Ellis LM. Significance of vessel count and vascular endothelial growth factor and its receptor (KDR) in intestinal-type gastric cancer. Clin Cancer Res 1996;2:1679-84.